Delivery Order SPE2DB25D3306-SPE2DB25FUBLD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180-count) valued at $1,412.73, with an ultimate completion date of June 5, 2025. This competitively awarded, non-set-aside delivery order employs firm fixed price terms and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,346.88 to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's broader indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Entresto 49 mg-51 mg tablets (180 count) with a ceiling value of $1,794.62. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,695.65 on September 10, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and a completion deadline of September 11, 2025. AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania serves as the place of performance. This delivery order represents a continuation of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count units) with a ceiling value of $8,348.51. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count). This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $44,169.98 and is scheduled for completion by July 29, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,922.93 to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180 count) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed price delivery order, issued without a set-aside designation, represents a competitive award under the company's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,532.48 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180 count) on August 29, 2025. This firm fixed-price, competitively awarded contract is scheduled for completion by September 2, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count) with a contract value of $15,742.28. This non-set-aside, competitively awarded delivery order carries a firm fixed price and is scheduled for completion by August 6, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 97 mg-103 mg tablets (60-count units) with a ceiling value of $2,242.17. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 21, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical vendor...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUBLDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count units) with a ceiling value of $15,577.90. This firm fixed-price delivery order, with an ultimate completion date of April 22, 2025, represents a non-set-aside competitive award executed under DLA's broader pharmaceutical supply chain. The place of performance is identified as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters as a major pharmaceutical distributor and critical federal medical procurement vendor. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As one of the company's extensive portfolio of federal medical supply contracts, this award demonstrates AmerisourceBergen's capability to deliver brand-name and generic pharmaceuticals to support military healthcare programs and other federal healthcare systems. The award reflects the company's consistent selection through competitive procurement processes and its ability to fulfill federal medical supply requirements across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 4/21/25 |